ARBs for cardiovascular and renal protection in high-risk patients.

摘要

The contribution of recent trials such as the extensive ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) 'a thorough, double-blind, prospective, randomised trial, which documents the equal-outcome efficacy of an ARB (telmisartan) and an ACE inhibitor in a high-risk population' is noted in a recent meta-analysis of ARBs. Among ARBs, telmisartan is further differentiated by both its pharmacokinetic and pharmacodynamic properties. It has a longer half-life and higher lipophilicity than other agents in the class.